Medical isotope and radiopharmaceutical supplier BWXT Medical has signed an agreement with Boston Scientific to manufacture that firm's TheraSphere yttrium-90 (Y-90) glass microspheres.
BWXT will produce the microspheres at its Ottawa, Canada facility. In March, Boston Scientific secured premarket approval for TheraSphere from the U.S. Food and Drug Administration. The microspheres are used to treat patients with hepatocellular carcinoma.
